FY2025 · ended Dec 31, 2025 · Revenue $5.21M, -10.5% YoY · Filed Mar 12, 2026
Cerenome, Inc. (CNSY) files with the SEC under industry code 3841, Surgical & Medical Instruments & Apparatus. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $5.2 million and a net loss of $22.4 million. Free cash flow was -$20.8 million. As of Jun 30, 2026 it held $8.6 million in cash and investments and $59,000 in total debt.
Revenue (TTM)
$4.20M
Net income (TTM)
$-26.09M
-37.1% vs year-ago TTM
Operating cash flow (TTM)
$-22.18M
-31.5% vs year-ago TTM
Free cash flow (TTM)
$-23.55M
-39.4% vs year-ago TTM
EPS (TTM)
$-0.32
+92.4% vs year-ago TTM
Dividend per share
None
Shares outstanding
171.55M
+909.1% vs prior year
Net cash
$8.53M
as of Jun 30, 2026
Operating margin
-628.1%
FY 2026
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- CNSY (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Houston, TX
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1095981
- Former names
- PLUS THERAPEUTICS, INC. (until Jul 1, 2026); CYTORI THERAPEUTICS, INC. (until Aug 2, 2019); MACROPORE INC (until Jul 5, 2005)
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Boston Scientific Corp BSX
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Resmed Inc RMD
- Dexcom Inc DXCM
- Fresenius SE & Co. KGaA FSNUY
All 151 Surgical & Medical Instruments & Apparatus companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $5.2M | $5.8M | — | — | — |
| Operating income | -$15.3M | -$14.7M | -$13.3M | -$19.7M | -$12.5M |
| Net income | -$22.4M | -$13.0M | -$13.3M | -$20.3M | -$13.4M |
| Diluted EPS | -$0.29 | -$2.34 | -$4.24 | -$11.58 | — |
| Operating cash flow | -$20.8M | -$10.6M | -$12.9M | -$13.0M | -$10.3M |
| Free cash flow | -$20.8M | -$10.7M | — | — | — |
| Total assets | $16.3M | $6.6M | $11.4M | $23.9M | $22.0M |
| Total liabilities | $12.3M | $15.6M | $12.7M | $17.4M | $11.1M |
| Stockholders' equity | $4.0M | -$8.9M | -$1.3M | $6.4M | $10.8M |
| Cash and investments | $8.6M | $3.6M | $8.6M | $18.1M | $18.4M |
| Total debt | $71,000 | $75,000 | $4.2M | $5.6M | $7.0M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Oct 2, 2026 | Oct 2, 2026 |
| 8-K |
Current report
Material agreement, New debt, Unregistered share sale, Other events
|
Sep 10, 2026 | Sep 4, 2026 |
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 14, 2026 | Aug 14, 2026 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Aug 4, 2026 | Aug 3, 2026 |
| 8-K |
Current report
Material agreement
|
Jun 5, 2026 | Jun 1, 2026 |
All 1000 Cerenome, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.